TriSalus Life Sciences Bets Big Amid FDA Delay

Trisalus Life Sciences, Inc. ((TLSI)) has held its Q1 earnings call. Read on for the main highlights of the call.

TriSalus Life Sciences’ latest earnings call blended confidence in its clinical and economic story with realism about near‑term financial drag. Executives leaned on fresh real‑world data to validate pressure‑enabled drug delivery (PEDD) and a growing pipeline, while acknowledging that salesforce expansion and an FDA delay are weighing on revenue and losses in the short run.

Landmark Real‑World Evidence Strengthens PEDD Value Proposition

TriSalus highlighted a landmark real‑world study comparing 603 PEDD patients to more than 16,200 treated with conventional approaches, drawn from a 300 million‑patient claims database. Results showed lower fatigue and complications, fewer inpatient stays after TACE, roughly 48% more doxorubicin delivered per procedure, and about $7,700 in downstream cost avoidance per patient.

Clinical Pipeline Scales with Multiple Ongoing and Pending Studies

Management underscored a robust evidence engine with 10 active studies across 24 sites and more than 400 TriNav‑treated patients. New randomized and prospective trials at Stanford and MD Anderson, plus two completed investigator‑initiated studies moving toward submission, are designed to deepen data in liver cancer and expand use in additional tumor settings.

Diversification Into New Indications Targets a $2.5 Billion Market

The company is pushing PEDD into non‑liver indications, citing striking uterine fibroid outcomes with nearly 97.5% median dominant fibroid volume reduction and no device‑related complications. Early results in thyroid disease and progress toward a formal genicular artery embolization trial support management’s estimate of a roughly $2.5 billion U.S. addressable market across liver and new applications.

Commercial Build‑Out and New Leadership Aim at Multi‑Year Growth

TriSalus more than doubled its sales organization and added a senior commercial leader to position for broader adoption. Around 60% of territories performed as expected during the transition while 40% saw planned disruption, and the company expects new representatives to reach typical productivity after about six to nine months, setting up a multi‑year growth trajectory.

Gross Margin Improvement and Cash Cushion Support Investment

Despite softer revenue, the company expanded gross margin to 86% from 84% a year earlier, helped by lower unit costs and manufacturing efficiencies. Cash and cash equivalents of $56.6 million at quarter‑end are framed as sufficient to fund the sales build‑out, pipeline work, and broader growth strategy without near‑term financing pressure.

Short‑Term Revenue Pressure from Commercial Transition

First‑quarter revenue slipped to $8.9 million from $9.2 million as territory realignment and onboarding kept a chunk of the salesforce out of the field. Management said roughly 40% of territories experienced intentional disruption tied to the reorganization, which is expected to normalize as new hires move along the six to nine‑month productivity curve.

Higher Operating Loss Reflects Growth Investments

The net operating loss widened to $8.4 million from $7.3 million, and adjusted EBITDA loss rose to about $5.8 million as TriSalus leaned into spending. Sales and marketing, R&D, and G&A all ticked higher, partly due to increased non‑cash stock‑based compensation, signaling a willingness to absorb near‑term losses to build scale.

FDA Delay for TriNav Advance Defers Upside

An unexpected setback came from the FDA review of TriNav Advance, which is now running about five months past the 30‑day review goal. While management still anticipates a second‑half clearance, they have stripped related advanced device revenue from internal second‑half expectations, tempering the near‑term growth profile.

Guidance Reset Frames a More Gradual Ramp

TriSalus revised its full‑year 2026 revenue outlook to $54 million to $57 million to reflect the slower start and TriNav Advance timing uncertainty. Leadership projects modest sequential improvement in the second quarter and a sharper step‑up in the second half, backed by durable mid‑80s gross margins and growing clinical and economic evidence as adoption catalysts.

TriSalus’ call painted a picture of a company trading near‑term earnings softness for long‑term strategic positioning, anchored by compelling PEDD data and a broadened commercial footprint. For investors, the story now hinges on execution: successful rep ramp‑up, regulatory clearance for TriNav Advance, and proof that the expanded pipeline and new indications can convert into sustained revenue growth.